Navigation Links
Stemedica Announces the Appointment of Dr. Csar Amescua Garcia as Medical and Regulatory Affairs Director – Latin America
Date:6/24/2010

Dr. Amescua will be responsible for liaison with regulatory agencies in Latin America regarding approvals of Stemedica’s allogeneic adult stem cell products for use in clinical (human) trials which follow the criteria required by the FDA in the United States.

(PRWEB) June 24, 2010 -- Stemedica Cell Technologies, Inc., a leader in allogeneic adult stem cell manufacturing, research and development announced today the appointment of César Amescua, MD as Medical and Regulatory Affairs Director for Latin America. Dr. Amescua will be responsible for liaison with regulatory agencies in Latin America regarding approvals of Stemedica’s stem cell products for use in clinical (human) trials which follow the criteria required by the FDA in the United States.

Dr. Amescua is a member of the senior medical leadership at Groupo Angeles, one of the largest health care providers in all of Latin America. He is also President of the Mexican Association for the Study and Treatment of Pain. "I am excited and proud to be working with Stemedica. The company is a leader in the stem cell manufacturing field, and is bringing innovative technology to countries around the world. Latin America holds great promise for Stemedica’s products and services as Latin America seeks to address the epidemic of degenerative diseases and conditions that are bankrupting health care systems around the world."

Dr. Lev Verkh, Stemedica’s Chief Regulatory and Clinical Development Officer, commented, "We’re pleased and delighted to have Dr. Amescua joining our team at Stemedica. His medical leadership and his regulatory expertise will be critical in establishing clinical trials throughout Latin America using Stemedica stem
'/>"/>

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Page: 1 2

Related biology technology :

1. Stemedica Announces the Appointment of Dr. Lev Verkh as Chief Regulatory and Clinical Development Officer
2. Stemedica Completes Meeting with the FDA
3. United States Patent and Trademark Office Publishes Stemedica's Patent Application for the Treatment of Diabetic Retinopathy
4. The Jordanian Stem Cell Company Acquires Stem Cell Technology From Stemedica International S.A. - First Clinical Trail Anticipated To Begin Early 2010
5. Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells
6. Stemedica Selected By World Stem Cell Summit To Present Scientific Discoveries
7. Stemedica Requests Pre-IND Meeting With FDA
8. Stemedica Signs Scientific Advisory Board Agreement with Leading Pediatric Burn & Wound Care Researcher
9. Renowned Stem Cell Researcher Files Study Results With Stemedica
10. CIRM Completes Briefing Visit to Stemedica Cell Technologies
11. Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Stemedica Announces the Appointment of Dr. Csar Amescua Garcia as Medical and Regulatory Affairs Director – Latin America 
(Date:4/30/2015)... N.J. , April 30, 2015  Roka Bioscience, ... focused on providing advanced testing solutions for the detection ... results for the first quarter of 2015 on May ... Roka Bioscience will also host a conference ... 2015 to discuss its first quarter financial results. During ...
(Date:4/30/2015)... 2015 Nitto Avecia, a leading ... increased capacity and production capability to serve biotechnology ... and service fulfillment continues to drive Nitto Avecia ... throughput capacities. , In Fall 2014, ... process equipment at its Milford, MA facility, which ...
(Date:4/30/2015)...  The Paul G. Allen Family Foundation announced today ... six groups of researchers with projects at the frontier ... growing mature human brain cells in the laboratory. The ... over three years.  "This new cohort ... significant because the field of neuronal maturation is at ...
(Date:4/30/2015)... April 30, 2015 WuXi PharmaTech (Cayman) Inc. ... leading global contract R&D services provider, today announced that ... proposal letter, dated April 29, 2015, from a consortium ... (the "Chairman"), founder, chairman and chief executive officer of ... that proposes a transaction (the "Transaction") involving the acquisition ...
Breaking Biology Technology:Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 4The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 5WuXi PharmaTech Announces Receipt of Proposal 2WuXi PharmaTech Announces Receipt of Proposal 3WuXi PharmaTech Announces Receipt of Proposal 4WuXi PharmaTech Announces Receipt of Proposal 5WuXi PharmaTech Announces Receipt of Proposal 6
... Annual Observance To Draw Attention To ,The Sneak Thief ... an effort to combat one of the,main causes of ... World Glaucoma Patient Organization have announced the first annual,World ... The day will be marked,by awareness and educational events ...
... and CLAREMONT, Calif., Jan. 30 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech ... the volume of bio-enhanced feed products sold during ... quarter of 2007 and increased,25% over the same ... Feed Co., Ltd. ("Kiwa Tianjin") is a joint-venture ...
... Tengion Inc., a clinical,stage regenerative medicine company focused ... that Steven Nichtberger, M.D.,President and Chief Executive Officer, ... Biotechnology and Medical Device Conference on,Tuesday, February 5, ... be held at,the Grand Hyatt Hotel in New ...
Cached Biology Technology:World Glaucoma Day Set for March 6th 2Kiwa Bio-Tech Animal Feed Volume Increased 25% in Fourth Quarter of 2007 2
(Date:4/14/2015)... 14, 2015  HYPR Corp. today announced it ... ) Alliance tm , an industry consortium transforming ... to share technology and collaborate to deliver open ... more secure and private, and easier to use. ... that protects sensitive user information and eliminates the ...
(Date:4/9/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the third quarter ... the close of market. The company will host a ... p.m. PT (5:00 p.m. ET), during which management may ... the live call, analysts and investors should dial 888-438-5524 ...
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2
... risks posed by pharmaceuticals are not enough to protect ... of Gothenburg (Sweden) who is calling for better environmental ... the combined effects of different drugs to reflect the ... Brosch from the Department of Plant and Environmental Sciences ...
... of scientists from Singapore led by the Genome Institute ... Cell Biology (IMCB), two biomedical research institutes of ... discovered the most important genes in human embryonic stem ... stem cells work. Their research, published in top scientific ...
... National Laboratory researcher Bette Korber is part of an ... the first human trial of a mosaic HIV vaccine ... the virus that causes AIDS by attempting to address ... design: the virus,s extensive genetic diversity. The team ...
Cached Biology News:Environmental risk assessment of pharmaceuticals inadequate 2Singapore scientists first to perform genome-wide study of human stem cells 2Consortium to design human trials of mosaic HIV vaccine 2
Rabbit polyclonal to hCG ( Abpromise for all tested applications). entrezGeneID: 1081 SwissProtID: P01215...
Anti-HumanLactoferrin...
Rabbit monoclonal [EP881Y] to EEF2K ( Abpromise for all tested applications). Antigen: Synthetic peptide corresponding to residues in the C-terminal of human EEF2K. Entrez GeneID: 29904 S...
ICAD Purified Anti-Mouse clone Polyclonal, Isotype Rabbit Ig, 200 µl Consult technical datasheet for details....
Biology Products: